SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as the community eagerly awaits imminent Phase 3 REGAL trial results, fueling strong conviction around GPS immunotherapy's potential for "curative" outcomes in AML. Investors are overwhelmingly bullish, dismissing persistent bearish takes from some while anticipating a significant short squeeze and potential for substantial buyout offers for its promising pipeline.

Aventus Network

Aventus Network ($AVT) is gaining attention following its formal DAO incorporation in the UAE and the appointment of a strategic advisor for regional expansion, alongside developments for its enterprise-focused Aventus Cloud. The community is actively discussing AVT's potential for a significant breakout, highlighting its low market capitalization, Polkadot integration, and enterprise-grade technology as key indicators, while closely monitoring for increased trading volume.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending with high anticipation for its R2 launch event, propelled by a recent analyst upgrade and the strong performance of its software division, as the community actively debates the stock's future potential amid rising energy costs boosting EV adoption.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the broader market experiences a significant rebound, primarily fueled by statements suggesting the Middle East conflict is nearing an end. However, this rally sparks intense community debate, with many traders questioning the legitimacy of the 'peace' narrative and labeling it an algo-driven 'fake pump' detached from current geopolitical realities.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its engaged community actively embraces the "What's UpDog?" meme, fueling bullish sentiment and highlighting its long-term presence on Solana with locked liquidity and a listing on the Jupiter Strict List.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its robust oncology pipeline delivers significant news, including positive Phase 3 data for a breast cancer drug and promising lung cancer therapy results, which has garnered a Goldman Sachs upgrade and shifted community focus towards its potential beyond COVID-19 vaccines.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending amidst strong anticipation for its upcoming earnings report, as the community actively discusses the potential for a significant short squeeze fueled by high short interest and optimistic outlooks on holiday sales. Bullish sentiment is further bolstered by discussions around the retailer's strategic turnaround and its undervalued real estate assets, countering broader concerns within the retail sector.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a significant Q4 EPS beat, signaling a pivotal shift to profitability driven by accelerating MIPLYFFA revenue growth, which the community believes makes the "hugely undervalued" stock ripe for a substantial re-rating with anticipated EMA approval on the horizon.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending following its substantial $250 billion commitment to US connectivity and strategic partnerships in fiber and satellite technology. The community is actively discussing strong earnings, a bullish long-term outlook, and significant shareholder return plans, positioning it as a key value play in the telecom sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is actively discussed following its proposed convertible senior notes offering, which raises community questions about management's strategy amid persistent buyout rumors and growing optimism for Casgevy's commercial ramp-up and positive early data from its zugo-cel program, including a new Eli Lilly partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $4,211,425.27 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 64,921 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at...

Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 64,921 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of...

GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO

GW&K Investment Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities...

BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar outlined the company's recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen's 46th Annual...

Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO

Aisling Capital Management LP raised its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 0.4% in the third quarter, according to the company in its most recent disclosure...

Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO

Rafferty Asset Management LLC decreased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.8% during the 3rd quarter, according to the company in its most recent...

Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO

Intech Investment Management LLC trimmed its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the...

Okabena Investment Services Inc. Makes New $816,000 Investment in BridgeBio Pharma, Inc. $BBIO

Okabena Investment Services Inc. acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and...

Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO

Monashee Investment Management LLC lessened its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 21.6% during the third quarter, according to the company in its most recent...

BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings

BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BBIO News

BBIOBridgeBio Pharma Inc